CYP17A1 intron mutation causing cryptic splicing in 17α-hydroxylase deficiency.

17α-hydroxylase/17, 20-lyase deficiency is a rare autosomal recessive disorder linked to CYP17A1 mutations. It causes congenital adrenal hyperplasia and hypertension with hypokalemia. Prior research has shown that CYP17A1 mutations disrupt enzyme activity, but the specific mechanisms of intronic mutations remain unclear. This gap motivated a closer look at how intronic changes affect mRNA splicing. No prior work had resolved how splice site mutations in CYP17A1 contribute to disease. It was already known that mutations in exonic regions cause enzyme dysfunction. This paper's contribution is to explore intronic mutations and their effects on splicing. The study aimed to clarify how a specific intronic mutation leads to defective enzyme activity. The research fills a gap in understanding the role of intronic splice sites in 17OHD.

The aim of the study was to investigate how an intronic mutation in the CYP17A1 gene affects mRNA splicing and enzyme function. The specific problem is understanding how splice donor site mutations contribute to 17α-hydroxylase deficiency. The motivation comes from the need to clarify the molecular mechanism behind this rare disorder. The researchers focused on a patient with clinical features of 17OHD. They sought to determine whether the intronic mutation causes cryptic splicing. The study aimed to test if this mutation leads to the inclusion of an intronic pseudo-exon. The goal was to assess the functional consequences of the IVS1 +2T>C mutation. This work aimed to provide a mechanistic explanation for the observed clinical phenotype.

The study used PCR and sequencing to identify mutations in the CYP17A1 gene. The patient was found to be a compound heterozygote for two mutations. The first intron splice donor site mutation was recreated in minigene and full-length vectors. Transfection experiments were performed to study mRNA splicing in transfected cells. A lymphoblastoid cell line was used to confirm the splicing defect. The splicing of the variant intron was analyzed in transfected cells. The researchers examined whether the mutation leads to inclusion of an intronic pseudo-exon. The functional consequences of the mutation were assessed using expression vectors.

The majority of mRNA transcripts in transfected cells showed incorrect splicing. Over 90% of transcripts included an intronic pseudo-exon due to the mutation. Only the p.R358X transcript was detected in the lymphoblastoid cell line. The IVS1 +2T>C mutation caused a frameshift and early termination of the protein. The mutation abolished most 17α-hydroxylase/17, 20-lyase enzyme activity. The splicing defect was confirmed in both minigene and full-length constructs. The aberrant splicing led to a non-functional enzyme product. These findings suggest that intronic mutations can severely disrupt enzyme function.

The IVS1 +2T>C mutation in CYP17A1 leads to cryptic splicing and enzyme dysfunction. The mutation causes inclusion of an intronic pseudo-exon in the mRNA. This results in a frameshift and early termination of the CYP17A1 protein. The patient's clinical features align with the predicted functional consequences. The study confirms that intronic splice site mutations can cause 17OHD. The findings suggest that such mutations disrupt normal splicing patterns. The authors propose that this mechanism explains the observed enzyme deficiency. These results provide insight into the molecular basis of the disease.